Use of annexin V-ferrofluid to enumerate erythrocytes damaged in various pathologies or during storage in vitro.

Recombinant human annexin V war bound covalently to 9 nm maghemite (gamma/Fe2O3) nanoparticles, yielding annexin-ferrofluid (AnxFF), and used to separate annexin-bound red blood cells (RBC) in a magnetic field and estimate their percentage in various bloods. Annexin binding in normal human RBC increased proportionately with storage from 8% on day 2 to 42% on day 100. Enhanced AnxFF binding was associated with various pathologies. Thus, normal blood contained 10.7+/-5.9% AnxFF binding RBC; bloods with normal sedimentation rates (albeit with some disease necessitating analysis) contained 23.5+/-6.2%, those with high sedimentation rates contained 51.5+/-12.3%; sickle cell anaemia patients' blood contained 50.0+/-3.3%, and bloods from patients with other pathologies (deforming rheumatic disease, cancer necessitating chemotherapy, etc.) contained 58.6+/-7.6% AnxFF binding RBC. Enhanced Ca2+-dependent annexin binding reflects a loss of the asymmetric distribution of anionic phospholipids in plasma membranes which may constitute a signal for the destruction of the modified cells by the reticuloendothelial system. Once these preliminary results are confirmed the determination of the fraction of AnxFF bound erythrocytes, following their magnetic separation, could prove a simple and rapid quality test for example in the concert of blood transfusion.